US mulls equity stakes in chipmakers receiving CHIPS Act Funds - Reuters
Mizuho Financial Group (NYSE:MFG) reiterated its Outperform rating and $110.00 price target on Insmed (NASDAQ:INSM), whose stock has surged 11.72% in the past week to $101.59, following positive Phase 2b trial results for the company’s trepostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH). According to InvestingPro data, analysts maintain a strong bullish consensus with price targets ranging from $90 to $125.
The research firm hosted an expert call Monday with a pulmonary disease key opinion leader to discuss the TPIP trial data released last week. The expert described the Phase 2 PAH results as "extremely positive" and estimated an 80% probability of success for TPIP in both PAH and pulmonary hypertension-interstitial lung disease (PH-ILD) indications. The market has responded positively to these developments, with InvestingPro showing the stock trading near its 52-week high of $101.70.
Mizuho’s expert characterized TPIP as a potential "existential threat" to competing treprostinil-based products currently on the market. The firm indicated the expert feedback suggests upside potential to their current TPIP revenue estimates. This optimism aligns with Insmed’s strong revenue growth of 20.77% over the last twelve months, as reported by InvestingPro, which offers 13 additional ProTips and comprehensive financial analysis for the company.
The investment bank described TPIP as a "potential game-changer" for both PAH and PH-ILD treatment. These conditions affect the blood vessels in the lungs and can lead to serious complications including heart failure.
Insmed’s TPIP represents a new delivery method for treprostinil, a vasodilator that helps widen blood vessels and improve blood flow. Mizuho has designated Insmed as its top stock pick for June 2025.
In other recent news, Insmed Incorporated announced a successful public offering of 7,812,500 shares of its common stock, expected to generate approximately $750 million in gross proceeds. The funds are earmarked for research and development, commercialization activities, and further development of their inhalation powder. In another development, RBC Capital raised its price target for Insmed to $106, citing positive data for the company’s TPIP treatment for pulmonary arterial hypertension. H.C. Wainwright also increased its price target to $120, following favorable Phase 2A and 2B study results for the same treatment. Mizuho raised its price target to $110, describing the TPIP data as "outstanding" and noting potential growth opportunities for Insmed. Additionally, Insmed announced a separate intention to offer $650 million in common stock, with the offering subject to market conditions. These developments highlight Insmed’s ongoing efforts to bolster its financial position and enhance its pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.